Patents by Inventor Sing-Yuen Sit

Sing-Yuen Sit has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 3-thia-4-arylquinolin-2-one derivatives
    Patent number: 7179920
    Abstract: This invention describes compounds of Formula (I) which are modulators of potassium channels and are useful for treating conditions affected by abnormal potassium channel activity including erectile dysfunction and irritable bowel syndrome
    Type: Grant
    Filed: October 13, 2004
    Date of Patent: February 20, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kenneth M. Boy, Piyasena Hewawasam, Sing-Yuen Sit
  • Potassium channel modulators
    Patent number: 7151180
    Abstract: This invention describes compounds of Formula (I) which are modulators of potassium channels and are useful for treating conditions affected by abnormal potassium channel activity including erectile dysfunction and irritable bowel syndrome.
    Type: Grant
    Filed: October 13, 2004
    Date of Patent: December 19, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Piyasena Hewawasam, Sing-Yuen Sit, John E. Starrett, Jr.
  • Chiral dinapsoline
    Patent number: 7091212
    Abstract: The present invention relates to the preparation of the optical isomer (R)-(+)-8,9-dihydroxy-2,3,7,11b-tetrahydro-1H-napth[1,2,3-de]isoquinoline. This invention also relates to the use of pharmaceutical compositions comprising (R)-(+)-8,9-dihydroxy-2,3,7,11b-tetrahydro-1H-napth[1,2,3-de]isoquinoline for use for the treatment of movement disorders.
    Type: Grant
    Filed: August 8, 2002
    Date of Patent: August 15, 2006
    Assignee: Purdue Research Foundation
    Inventor: Sing-Yuen Sit
  • Hepatitis C virus inhibitors
    Publication number: 20060172950
    Abstract: Hepatitis C virus inhibitors are disclosed having the general formula: wherein R1, R2, R3, R?, B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
    Type: Application
    Filed: December 7, 2005
    Publication date: August 3, 2006
    Inventors: Xiangdong Wang, Li-Qiang Sun, Sing-Yuen Sit, Ny Sin, Paul Scola, Piyasena Hewawasam, Andrew Good, Yan Chen, Jeffrey Campbell
  • 3-Thia-4-arylquinolin-2-one potassium channel modulators
    Patent number: 7049309
    Abstract: This invention describes compounds of Formula (I) which are modulators of potassium channels and are useful for treating conditions affected by abnormal potassium channel activity including erectile dysfunction and irritable bowel syndrome.
    Type: Grant
    Filed: October 13, 2004
    Date of Patent: May 23, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kenneth M. Boy, Piyasena Hewawasam, Sing-Yuen Sit, Kai Xie
  • Hepatitis C virus inhibitors
    Patent number: 6995174
    Abstract: Hepatitis C virus inhibitors are disclosed having the general formula: wherein R1, R2, R3, R?, B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
    Type: Grant
    Filed: May 20, 2003
    Date of Patent: February 7, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Xiangdong Alan Wang, Li-Qiang Sun, Sing-Yuen Sit, Ny Sin, Paul Michael Scola, Piyasena Hewawasam, Andrew Charles Good, Yan Chen, Jeffrey Allen Campbell
  • (Oxime)carbamoyl fatty acid amide hydrolase inhibitors
    Patent number: 6949574
    Abstract: The present invention relates to novel oxime carbamyl derivatives and pharmaceutical compositions comprising said derivatives which inhibit fatty acid amide hydrolase. These pharmaceutical compositions are useful for the treatment of conditions which can be effected by inhibiting fatty acid amide hydrolase including, but not limited to, neuropathic pain, emesis, anxiety, altering feeding behaviors, movement disorders, glaucoma, brain injury, and cardiovascular disease.
    Type: Grant
    Filed: February 4, 2003
    Date of Patent: September 27, 2005
    Assignee: Bristol-Myers Squibb Company
    Inventors: Sing-Yuen Sit, Kai Xie, Hongfeng Deng
  • 3-Thia-4-arylquinolin-2-one potassium channel modulators
    Publication number: 20050176763
    Abstract: This invention describes compounds of Formula (I) which are modulators of potassium channels and are useful for treating conditions affected by abnormal potassium channel activity including erectile dysfunction and irritable bowel syndrome.
    Type: Application
    Filed: October 13, 2004
    Publication date: August 11, 2005
    Inventors: Kenneth Boy, Piyasena Hewawasam, Sing-Yuen Sit, Kai Xie
  • (Oxime)carbamoyl fatty acid amide hydrolase inhibitors
    Publication number: 20050131032
    Abstract: The present invention relates to novel oxime carbamyl derivatives and pharmaceutical compositions comprising said derivatives which inhibit fatty acid amide hydrolase. These pharmaceutical compositions are useful for the treatment of conditions which can be effected by inhibiting fatty acid amide hydrolase including, but not limited to, neuropathic pain, emesis, anxiety, altering feeding behaviors, movement disorders, glaucoma, brain injury, and cardiovascular disease.
    Type: Application
    Filed: January 19, 2005
    Publication date: June 16, 2005
    Inventors: Sing-Yuen Sit, Kai Xie, Hongfeng Deng
  • Potassium channel modulators
    Publication number: 20050080082
    Abstract: This invention describes compounds of Formula (I) which are modulators of potassium channels and are useful for treating conditions affected by abnormal potassium channel activity including erectile dysfunction and irritable bowel syndrome.
    Type: Application
    Filed: October 13, 2004
    Publication date: April 14, 2005
    Inventors: Piyasena Hewawasam, Sing-Yuen Sit, John Starrett
  • 3-thia-4-arylquinolin-2-one derivatives
    Publication number: 20050080105
    Abstract: This invention describes compounds of Formula (I) which are modulators of potassium channels and are useful for treating conditions affected by abnormal potassium channel activity including erectile dysfunction and irritable bowel syndrome.
    Type: Application
    Filed: October 13, 2004
    Publication date: April 14, 2005
    Inventors: Kenneth Boy, Piyasena Hewawasam, Sing-Yuen Sit
  • Hepatitis C virus inhibitors
    Publication number: 20040106559
    Abstract: Hepatitis C virus inhibitors are disclosed having the general formula: 1
    Type: Application
    Filed: May 20, 2003
    Publication date: June 3, 2004
    Inventors: Xiangdong Alan Wang, Li-Qiang Sun, Sing-Yuen Sit, Ny Sin, Paul Michael Scola, Piyasena Hewawasam, Andrew Charles Good, Yan Chen, Jeffrey Allen Campbell
  • Chiral dinapsoline
    Publication number: 20040063741
    Abstract: The present invention relates to the preparation of the optical isomer (R)-(+)-8,9-dihydroxy-2,3,7,11b-tetrahydro-1H-napth[1,2,3-de]isoquinoline. This invention also relates to the use of pharmaceutical compositions comprising (R)-(+)-8,9-dihydroxy-2,3,7,11b-tetrahydro-1H-napth[1,2,3-de]isoquinoline for use for the treatment of movement disorders.
    Type: Application
    Filed: April 2, 2003
    Publication date: April 1, 2004
    Inventor: Sing-Yuen Sit
  • Process for the preparation of dinaposoline
    Patent number: 6645975
    Abstract: The present invention relates to a novel process for the preparation of compounds of the formula wherein R1, R2, R4, R5, R6 and A are as defined herein, and to certain derivations of Formula IX which are useful for the treatment of movement disorders.
    Type: Grant
    Filed: January 27, 2003
    Date of Patent: November 11, 2003
    Assignee: Purdue Research Foundation
    Inventors: Sing-Yuen Sit, Swanee E. Jacutin-Porte
  • (Oxime)carbamoyl fatty acid amide hydrolase inhibitors
    Publication number: 20030195226
    Abstract: The present invention relates to novel oxime carbamyl derivatives and pharmaceutical compositions comprising said derivatives which inhibit fatty acid amide hydrolase. These pharmaceutical compositions are useful for the treatment of conditions which can be effected by inhibiting fatty acid amide hydrolase including, but not limited to, neuropathic pain, emesis, anxiety, altering feeding behaviors, movement disorders, glaucoma, brain injury, and cardiovascular disease.
    Type: Application
    Filed: February 4, 2003
    Publication date: October 16, 2003
    Inventors: Sing-Yuen Sit, Kai Xie, Hongfeng Deng
  • Bisarylimidazolyl fatty acid amide hydrolase inhibitors
    Patent number: 6562846
    Abstract: The present invention relates to bisarylimidazolyl derivatives and pharmaceutical compositions comprising said compounds inhibiting fatty acid amide hydrolase and useful for the treatment of pain, particularly neuropathic pain, psychomotor disorder, hypertension, cardiovascular disease, eating disorder, nausea, AIDS-related complex, glaucoma, inflammation, psoriasis or multiple sclerosis, and other conditions the treatment of which can be effected by inhibiting fatty acid amide hydrolase.
    Type: Grant
    Filed: April 23, 2002
    Date of Patent: May 13, 2003
    Assignee: Bristol-Myers Squibb Company
    Inventors: Sing-Yuen Sit, Kai Xie
  • Bisarylimidazolyl fatty acid amide hydrolase inhibitors
    Publication number: 20020188009
    Abstract: The present invention relates to bisarylimidazolyl derivatives and pharmaceutical compositions comprising said compounds inhibiting fatty acid amide hydrolase and useful for the treatment of pain, particularly neuropathic pain, psychomotor disorder, hypertension, cardiovascular disease, eating disorder, nausea, AIDS-related complex, glaucoma, inflammation, psoriasis or multiple sclerosis, and other conditions the treatment of which can be effected by inhibiting fatty acid amide hydrolase.
    Type: Application
    Filed: April 23, 2002
    Publication date: December 12, 2002
    Inventors: Sing-Yuen Sit, Kai Xie
  • Alkylamine derivatives of dihydropyridine NPY antagonists
    Patent number: 6479482
    Abstract: A series of non-peptidergic antagonists of NPY have been synthesized and are comprises of amino and piperazine derivatives of 4-phenyl-1,4-dihydropyridines of Formula 1. where X is CH or N As antagonists of NPY-induced behavior, these compounds are expected to act as effective anorexiant agents in promoting weight loss and treating eating disorders.
    Type: Grant
    Filed: May 10, 2001
    Date of Patent: November 12, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventors: Graham S. Poindexter, Marc Bruce, Sing-Yuen Sit, Scott W. Martin
  • 4-alkyl and 4-cycloalkyl derivatives of dihydropyridine NPY antagonists
    Patent number: 6444675
    Abstract: A series of non-peptidergic antagonists of NPY have been synthesized and are comprised of 4-alkyl and cycloalkyl derivatives of dihydropyridines of Formula I. As antagonists of NPY-induced behavior, these compounds are expected to act as effective anorexiant agents in promoting weight loss and treating eating disorders.
    Type: Grant
    Filed: April 24, 2001
    Date of Patent: September 3, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventor: Sing-Yuen Sit
  • Squarate derivatives of dihydropyridine NPY antagonists
    Patent number: 6432960
    Abstract: A series of antagonists of NPY have been synthesized and are comprised of squarate derivatives of 4-phenyl-1,4-dihydropyridines of Formula (I). As antagonists of NPY-induced behavior, these compounds are expected to act as effective anorexiant agents in promoting weight loss and treating eating disorders.
    Type: Grant
    Filed: April 24, 2001
    Date of Patent: August 13, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventors: Sing-Yuen Sit, Graham S. Poindexter